AU2021254856A1 - CER-001 therapy for treating kidney disease - Google Patents

CER-001 therapy for treating kidney disease Download PDF

Info

Publication number
AU2021254856A1
AU2021254856A1 AU2021254856A AU2021254856A AU2021254856A1 AU 2021254856 A1 AU2021254856 A1 AU 2021254856A1 AU 2021254856 A AU2021254856 A AU 2021254856A AU 2021254856 A AU2021254856 A AU 2021254856A AU 2021254856 A1 AU2021254856 A1 AU 2021254856A1
Authority
AU
Australia
Prior art keywords
cer
regimen
subject
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021254856A
Other languages
English (en)
Inventor
Ronald Barbaras
Laura CALABRESI
Jean-Louis Dasseux
Constance PEYROTTES
Cyrille TUPIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abionyx Pharma SA
Original Assignee
Abionyx Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000021 external-priority patent/WO2021209808A1/en
Application filed by Abionyx Pharma SA filed Critical Abionyx Pharma SA
Publication of AU2021254856A1 publication Critical patent/AU2021254856A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
AU2021254856A 2020-04-16 2021-04-15 CER-001 therapy for treating kidney disease Pending AU2021254856A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011048P 2020-04-16 2020-04-16
US63/011,048 2020-04-16
US202063092072P 2020-10-15 2020-10-15
US63/092,072 2020-10-15
PCT/IB2021/000021 WO2021209808A1 (en) 2020-04-16 2021-01-07 Cer-001 therapy for treating kidney disease
AUPCT/IB2021/000021 2021-01-07
PCT/IB2021/000282 WO2021209822A1 (en) 2020-04-16 2021-04-15 Cer-001 therapy for treating kidney disease

Publications (1)

Publication Number Publication Date
AU2021254856A1 true AU2021254856A1 (en) 2022-11-10

Family

ID=76034906

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021254856A Pending AU2021254856A1 (en) 2020-04-16 2021-04-15 CER-001 therapy for treating kidney disease

Country Status (10)

Country Link
US (3) US11752163B2 (https=)
EP (1) EP4135838A1 (https=)
JP (1) JP2023522055A (https=)
KR (1) KR20230004606A (https=)
CN (1) CN115666720A (https=)
AU (1) AU2021254856A1 (https=)
CA (1) CA3177735A1 (https=)
IL (1) IL297046A (https=)
MX (1) MX2022012906A (https=)
WO (1) WO2021209822A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984286T3 (es) * 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
IL297046A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Treatment of kidney disease using cer-001
KR20240018430A (ko) * 2021-04-15 2024-02-13 아비오닉스 파마 에스에이 기관 보존 용액에서의 지질 결합 단백질-기반 복합체의 사용
CA3247588A1 (en) * 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
JP2025519606A (ja) * 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
WO2023237927A2 (en) * 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
EP1545576A2 (en) 2002-07-30 2005-06-29 Esperion Therapeutics Inc. Methods of using non-human animal apoliprotein a-i protein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
LT2939683T (lt) * 2009-02-16 2017-03-27 Cerenis Therapeutics Holding Sa Apolipoproteino a-i mimetikai
EP2673296B1 (en) 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
AU2012236889A1 (en) 2011-03-25 2013-05-09 The Trustees Of Columbia University In The City Of New York Pegylated human HDL particle and process for production thereof
US9938312B2 (en) 2011-03-25 2018-04-10 University Of Georgia Research Foundation, Inc. Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans
JP6438417B2 (ja) 2013-03-15 2018-12-12 セレニス セラピューティクス ホールディング エスアー スフィンゴミエリンおよびジヒドロスフィンゴミエリンの合成のための方法
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
WO2015173633A2 (en) * 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016085986A1 (en) 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
WO2018022511A1 (en) * 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
EP3490579B1 (en) * 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
WO2018029505A1 (en) * 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
FR3100715B1 (fr) 2019-09-12 2023-09-29 Francais Du Sang Ets Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte
IL297046A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Treatment of kidney disease using cer-001
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
WO2021209808A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease

Also Published As

Publication number Publication date
MX2022012906A (es) 2023-03-14
CN115666720A (zh) 2023-01-31
US20210322448A1 (en) 2021-10-21
EP4135838A1 (en) 2023-02-22
US12364705B2 (en) 2025-07-22
WO2021209822A1 (en) 2021-10-21
KR20230004606A (ko) 2023-01-06
US11752163B2 (en) 2023-09-12
US20240016824A1 (en) 2024-01-18
CA3177735A1 (en) 2021-10-21
IL297046A (en) 2022-12-01
JP2023522055A (ja) 2023-05-26
US20250312366A1 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
US12364705B2 (en) CER-001 therapy for treating kidney disease
WO2021209808A1 (en) Cer-001 therapy for treating kidney disease
Havel Remnant lipoproteins as therapeutic targets
Klop et al. A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy
US20080214438A1 (en) Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content
US8030281B2 (en) Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
Ossoli et al. CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency
AU2003268190B2 (en) Treating Alzheimers using delipidated protein particles
Tomkin et al. Lipoprotein metabolism and alterations induced by insulin resistance and diabetes
Barbagallo et al. Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end‐stage renal disease patients
Pan et al. Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes
Heidelbaugh Lipid Disorders: A Multidisciplinary Approach, Clinics Collections, 1e,(Clinics Collections): Lipid Disorders: A Multidisciplinary Approach, Clinics Collections, 1e,(Clinics Collections)
Kwiterovich Jr et al. Diagnosis and treatment of dyslipoproteinemias in children and adolescents
Abdelhamid Glycosylphosphatidylinositol-verankertes Lipoprotein-Bindungsprotein 1 (GPIHBP1) Autoantikörper vermittelt ausgeprägte Chylomicronemie und ihre Behandlung
Björnson et al. Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target
Bawakhan Association Between Nutritional Indicators and Hemodialysis Adequacy in End Stage Renal Disease Patients Attending Nephrology Unit in Kims, Hubli
TW202604472A (zh) 包含15-hepe之組成物及治療或預防血液學病症及/或相關疾病之方法
Mazza et al. Efficacy and Safety of Dif1stat? for the Treatment of Secondary Dyslipidemia in Chronic Kidney Disease
Abdelhamid Aus der medizinischen Klinik und Poliklinik Gemeinschaftsklinikum Mittelrhein, Akademisches Lehrkrankenhaus der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Hassanali Characterization of a novel model of intestinal lipoprotein overproduction and the impact of N-3 PUFA supplementation
Klop Interplay between lipoproteins, the complement system and blood cells in
HK1087945B (en) Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
HK1087945A (en) Methods and apparatus for creating particle derivatives of hdl with reduced lipid content